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Interference of RNA (RNAi-SiRNA)
 Small ribonucleic acid (RNA) can act as a specific 
regulator of gene expression. This discovery has been an 
exciting breakthrough in Biological Sciences of the past 
decade, climax in last year’s Nobel Prize in Physiology 
or Medicine awarded to Andrew Fire and Craig Mello in 
2006. Building on previous work mainly in plants found 
that exogenous double-stranded RNA can be used to 
specifically interfere with gene function. This event was 
called RNA interference (RNAi) (Kozielski et al., 2013; 
Nishimura et al., 2013). They also consider that organisms 
might use double-stranded RNA naturally as a way of 
silencing genes. It was then shown that RNA interference 
was mediated by 22 nucleotide single-stranded RNAs 
termed small interfering RNAs (siRNAs) derived from 
the longer double-stranded RNA precursors (Schott et al., 
2012). The small interfering RNAs were discovered to 
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Abstract
 Since the first report of RNA interference (RNAi) less than a decade ago, this type of molecular intervention 
has been introduced to repress gene expression in vitro and also for in vivo studies in mammals. Understanding 
the mechanisms of action of synthetic small interfering RNAs (siRNAs) underlies use as therapeutic agents in 
the areas of cancer and viral infection. Recent studies have also promoted different theories about cell-specific 
targeting of siRNAs. Design and delivery strategies for successful treatment of human diseases are becomingmore 
established and relationships between miRNA and RNAi pathways have been revealed as virus-host cell 
interactions. Although both are well conserved in plants, invertebrates and mammals, there is also variabilityand 
a more complete understanding of differences will be needed for optimal application. RNA interference (RNAi) is 
rapid, cheap and selective in complex biological systems and has created new insight sin fields of cancer research, 
genetic disorders, virology and drug design. Our knowledge about the role of miRNAs and siRNAs pathways 
in virus-host cell interactions in virus infected cells is incomplete. There are different viral diseases but few 
antiviral drugs are available. For example, acyclovir for herpes viruses, alpha-interferon for hepatitis C and B 
viruses and anti-retroviral for HIV are accessible. Also cancer is obviously an important target for siRNA-based 
therapies, but the main problem in cancer therapy is targeting metastatic cells which spread from the original 
tumor. There are also other possible reservations and problems that might delay or even hinder siRNA-based 
therapies for the treatment of certain conditions; however, this remains the most promising approach for a wide 
range of diseases. Clearly, more studies must be done to allow efficient delivery and better understanding of 
unwanted side effects of siRNA-based therapies. In this review miRNA and RNAi biology, experimental design, 
anti-viral and anti-cancer effects are discussed. 
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suppress genes by removing the corresponding messenger 
RNA transcripts, and thus, blocking protein synthesis. 
SiRNAs regulate the degradation of mRNA molecules 
identical in sequence to that of the corresponding siRNA, 
resulting in the silencing of the corresponding gene and 
the shutting down of protein synthesis (Luo et al., 2004; 
Overhoff et al., 2005). The main mechanism of action 
of siRNA is the mRNA cleavage function. There are no 
genes that encode for siRNAs. siRNAs can also make 
gene expression silence by triggering promoter gene 
methylation and chromatin condensation (de Almeida et 
al., 2008; Dua et al., 2011; Chen et al., 2012).
 
Micro RNAs (miRNAs)
 The first miRNA was discovered in 1993 by 
Victor Ambros and colleagues Rosalind Lee and 
Rhonda Feinbaum. A genetic screen in the roundworm 
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Caenorhabditis elegans, a millimeter-long animal used 
as a model organism in biological research, recognized 
genes involved in developmental timing (Cevec et al., 
2010). Surprisingly, one of the genes, termed lin-4, did 
not encode a protein but instead a new 22-nucleotide 
small RNA. Seven years later, Reinhart et al. discovered 
a second 22-nucleotide small RNA of this type, let-7, a 
gene also involved in C elegans developmental timing 
(Cevec et al., 2008). The lin-4 and let-7 small regulatory 
RNAs soon became very exciting for two reasons. 
Firstly, similar let-7 gene were identified in other animals 
including humans. The conservation of let-7 across 
species suggested an important and essential biological 
role for this small RNA (Zhu et al., 2011). Secondly, the 
mechanism of RNA interference (RNAi) was discovered 
at that time, and it became clear that miRNA and RNAi 
pathways were intricately linked and shared common 
constituents. Within the following year, more than 100 
additional small regulatory RNAs similar to lin-4 and 
let-7 were identified in worms, the fruit fly Drosophila, 
and in humans These small non-coding RNAs were named 
microRNAs (miRNAs) (Schott et al., 2012).
Compare between SiRNA and miRNA
 Comparing with siRNAs, miRNAs are encoded by 
specific miRNA genes as short hairpin pri-miRNAs in 
the nucleus miRNAS are also small noncoding RNAs, 
but they seem to need only a 7-8base-pair “seed” match 
between the 5’ region of the miRNA and the 3’UTR of 
the target (Auyeung et al., 2013). It would seem that the 
majority of miRNA targets are translationally repressed; 
however, reduction of the target mRNA can also happen. 
The main mechanism of action of miRNA may be the 
inhibition of mRNA translation, although the cleavage of 
mRNA is also an important role (Figure 1) (Branscheid, et 
al., 2011). siRNAs are synthesized from double-stranded 
segments of matched mRNA via RNA-dependent RNA 
polymerase. miRNAs are synthesized from an unmatched 
segment of RNA precursor featuring a hairpin turn. 
siRNAs are often extracted from repetitive DNA sequences 
and associated transposons and centromeres, forming 
heterochromatin structures (Tsutsumi, et al., 2011). Both 
siRNAs and miRNAs are produced by Dicer-mediated 
cleavage of longer double-stranded RNA precursors. 
However, miRNAs are completely endogenous, whereas 
siRNAs may be endogenous or xogenously derived from 
viruses (Figure 2). Also, miRNAs cluster in “families” 
closely related as far as the sequence is concerned or as 
individual units. siRNAs can exist as repeated elements. 
Although miRNAs and siRNAs are inhibitors of specific 
mRNAs and both are under extreme study in anticancer 
drug development and there are significant differences 
between them which are highlighted in Table 1 (Monteys 
et al., 2010). Transcriptional profiling data have shown 
that the expression of miRNAs is highly normal in 
tissue and tumor-specific. miRNAs have been localized 
in chromosomal loci in the human genome associated 
with cancer, including fragile sites and areas of gene 
amplification (Lee, et al., 2011). Gains and losses of 
miRNA expression have been associated with cancer 
development and progression. However, the evidence 
that miRNAs directly participate in cancer development 
is limited (Chatterjee et al., 2013). 
 
Mechanisms of RNA Interference in 
Mammalian Cells
As shown in the Figure 2 pathway at the bottom 
left, cytoplasmic double-stranded RNAs (dsRNAs) 
are processed by a complex consisting of Dicer, TAR 
RNA-binding protein (TRBP) and protein activator of 
protein kinase PKR (PACT) into small interfering RNAs 
(siRNAs),which are loaded into Argonaute 2 (AGO2) 
and the RNA-induced silencing complex (RISC). The 
siRNA guide strand recognizes target sites to direct 
mRNA cleavage, which is carried out by the catalytic 
domain of AGO2. siRNAs complementary to promoter 
regions direct transcriptional gene silencing in the nucleus 
through chromatin changes involving histone methylation 
Figure 1. The Main Mechanism of Action of miRNA 
may be the Inhibition of mRNA Translation (Izquierdo, 
2005)
Figure 2. Comparison between siRNA and miRNA 
Pathways (Kanasty et al., 2012)
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(top left); the precise molecular details of this pathway 
in mammalian cells are currently unclear. As shown in 
the pathway on the right, endogenously encoded primary 
microRNA transcripts (pri-miRNAs) are transcribed by 
RNA polymerase II (Pol II) and initially processed by 
Drosha–DGCR8 (DiGeorge syndrome critical region gene 
8) to generate precursor miRNAs (pre-miRNAs). These 
precursors are exported to the cytoplasm by exportin 5 and 
subsequently bind to the Dicer–TRBP–PACT complex, 
which processes the pre-miRNA for loading into AGO2 
and RISC. The mature miRNA recognizes target sites 
in the 3’ untranslated region (3’ UTR) of mRNAs to 
direct translational inhibition and mRNA degradation in 
processing (P)-bodies that contain the decapping enzymes 
DCP1 and DCP2 (Geoghegan, et al., 2012; Kim et al., 
2007) (Figure 3).
RISC Loading and Activation
Double-stranded RNAs (dsRNAs) and precursor 
microRNAs (pre-miRNAs) are processed by a complex 
comprising Dicer, TAR RNA-binding protein (TRBP) 
and protein activator of protein kinase PKR (PACT), 
facilitating loading of the small interfering RNA (siRNA) 
or microRNA (miRNA) duplex into Argonaute 2 (AGO2) 
and RNA-induced silencing complex (RISC) (Gu et al., 
2012). When the RNA duplex loaded into RISC has 
perfect sequence complementarity, AGO2 cleaves the 
passenger strand so that active RISC is produced that 
contains the guide strand,which is complementary to the 
target sequence (Rand et al., 2005; Ye et al., 2011). When 
the RNA duplex loaded into RISC has imperfect sequence 
complementarity a bypass mechanism is used, in which a 
helicase activity is required to unwind the passenger strand 
from the guide strand and to generate the mature miRNA 
strand, producing active RISC (Kim, 2007) (Figure 4).
Immunostimulatory Effects  of  RNA 
Interference
Double-stranded RNAs (dsRNAs) longer than 30 
base pairs activate protein kinase R (PKR) and induce 
an interferon (IFN) response, as do blunt-ended, small 
interfering RNAs (siRNAs),which are detected by 
RIG-I (Lu et al., 2011). siRNAs that are incorporated 
into endosomes can activate Toll-like receptors (TLRs), 
depending on the presence of immunostimulatory motifs, 
inducing a type I interferon response by activating the 
transcription factors nuclear factor-κB (NFκB), activating 
transcription factor 2 (ATF2) and interferon regulatory 
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Table 1. Comparison Properties in SiRNA and miRNA
Properties SiRNA MiRNA
Primary mode of action Inhibition of translation mRNA cleavage
Secondary mode of action  mRNA cleavage Chromatin silencing
Encoded by genes in nucleus  Yes No
Matched RNA source Yes No
Synthesis Endogenous Endogenous or exogenous dsRNA
Phylogenitically conserved  Yes No
Synthesis enzymes RNA depended -RNA polymerase , Dicer RNA polymerase II , Drosha,Dicer
Precursor stage  Nucleus Nucleus
Length  19-23 bp 19-24 bp
Potential use in cancer diagnosis  Unknown Yes
Cancer prognostic significance Unknown Yes
Use in research and drug discovery Yes Yes
Figure 3. Mechanisms of RNA Interference in 
Mammalian Cells (Daniel et al., 2007). H3K9, histone 3 
lysine 9; H3K27, histone 3 lysine 27;m7G, 7-methylguanylate; 
ORF, open reading frame
Figure 4. RISC Loading and Activation (Daniel et al., 
2007)
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factor (IRF) (Xu et al., 2009; Sioud et al., 2010) (Figure 5).
miRNA and Cancer Diagnosis
The miRNA signature seems to be specific for a given 
normal tissue or malignancy. Investigators have reported 
that the miRNA signatures for poorly differentiated human 
neoplasms are more tumor-specific than the corresponding 
mRNA expression patterns (Cao et al., 2011). Moreover, 
profiling for miRNA expression in human solid tumors 
has confirmed a number of miRNAs as potential targets 
of anticancer therapy (Castaneda et al., 2011). In 2005, 
three reports provided the first mechanistic insight into 
how miRNAs might contribute to carcinogenesis. Two 
independent studies described the relationship between 
a miRNA cluster, mir-17-92, and the Myc oncogenic 
pathway (Jay et al., 2007). A third report demonstrated 
an interaction between let-7 miRNA and the RAS 
proto-oncogene . mir-17–92, is shown to be a potential 
oncogene by its action in an in vivo model of human B-cell 
lymphoma (Mitani et al., 2013). A cluster of microRNAs 
on human chromosome 13 has been found to be regulated 
by c-Myc, an important transcription factor that is 
overexpressed in many human cancers. And analysis of 
microRNA expression in over 300 individuals shows that 
microRNA profiles could be of value in cancer diagnosis 
(Chaulk et al., 2011; Zhao et al., 2013).
miRNA and Cancer Progression
A series of studies published during the last 2-3 years 
have displayed the association of miRNA expression 
with opposed outcome in a variety of human tumors. 
The profiles of miRNA expression have been linked to 
aggressive cancers with advanced disease detected at 
diagnosis (Tie et al., 2009). The study of miRNAs and 
cancer progression has focused on 3 major biological 
pathways: cell adhesion, angiogenesis, and cell matrix 
digestion and signaling. The transcription factor E2F1 
exhibits dual properties, acting as a tumor suppressor 
and oncogene (Knoll et al., 2013). Cellular stress such as 
DNA damage or mitogenic signaling leads to the activation 
of E2F1 as a mediator of apoptosis in the context of a 
conserved cellular anti-tumorigenic protects mechanism. 
However in highly aggressive chemo resistant tumors 
like malignant melanoma and prostate/bladder cancer 
it switches off this role and acts as promoter of cancer 
progression (Leite et al., 2013). Possible reasons for 
E2F1 mediated aggressiveness are defects in cell death 
pathways caused by epigenetic inactivation of important 
tumor suppressor genes, which often occur in late stage 
cancer and contribute to chemo resistance (Tchernitsa et 
al., 2010). Nevertheless exact mechanisms underlying 
E2Fs role in intrusiveness and metastasis are largely 
unknown. Different reports intimate towards the existence 
of feedback loops between E2F1 and microRNAs. 
miRNAs are activated by E2F1 and either the transcription 
factor itself or cellular genes necessary for the growth 
regulating function of E2F1 are inhibited by different 
miRNAs (Kim et al., 2013; Knoll et al., 2013; Paterson 
et al., 2013). This interactive regulation possibly impacts 
the balance between E2F1s proapoptotic in contrast to 
prosurvival function. In the following we will summarize 
some miRNA E2F1interactions contributing to a complex 
regulatory network (Figure 6) (Knoll et al., 2013).
miRNA as a Target for Cancer Treatment 
Given the aforementioned associations of miRNAs 
with cancer development and progression, it is now held 
that these small regulatory RNAs could serve as targets 
of anticancer gene therapies (Avci et al., 2013). The 
antisense technology based on antagomiRs is the major 
method used to reduce unwanted miRNA expression 
in tumor cells. AntagomiRs have been progressively 
improved by chemically modified oligonucleotides, 
providing more stability and affinity to the target miRNA 
and, consequently, more efficiency than their natural 
counterparts (Connelly et al., 2012). Antisense molecules 
can inhibit the activity of oncogenic miRNAs, and these 
have been tested for their efficacy in a strategy of reducing 
miRNA activity on reporter genes bearing miRNA-binding 
sites (Krutzfeldt et al., 2005). Antagomirs represent a new 
class of oligonucleotides designed to antagonize specific 
Figure 5. Immunostimulatory Effects of RNA 
Interference (Daniel et al., 2007). MyD88, myeloid 
differentiation primary response gene 88;TRIF, TLR-signalling 
adaptor protein
Figure 6. Role of miRNAs in Cell Signaling (Sihan et 
al., 2013)
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miRNAs. miRNAs that function as tumor suppressors 
can also be lost in cancer, as well as overexpressed. 
Thus, alternative approaches toward the targeting of 
miRNAs in novel cancer therapies would be the use of 
viral vectors or small molecules or compounds to restore 
the expression of these lost miRNAs and simultaneously 
repress the expression of the corresponding target gene 
(Krutzfeldt et al., 2007). For example, in a recent study, 
inhibition of miR-200c using an anti-miRNA 2’-0-methyl 
oligonucleotide resulted in an increase in expression 
of one of the targets, the transcription factor TCF8. In 
2008, the first clinical trial using miRNA-based therapy 
began. A phase I trial was initiated to treat hepatitis C 
using a LNAoligonucleotide complementary to miR-
122 to inhibit the expression of this oncogenic miRNA, 
which normally facilitates virus replication (Scherr et al., 
2010). In 2010, the success of this clinical trial and the 
beginning of phase II was announced .Despite the fact 
that this is the only study addressing the manipulation of 
a specific miRNA expression, several other clinical trials 
are currently being performed, aiming at the treatment 
of several diseases, such as asthma, leukemia, and other 
cancer types (Castaneda et al., 2011; Ye et al., 2013; Zhu 
et al., 2013).
Antiviral Mechanism of RNAi 
Infection by all RNA viruses, except retroviruses, 
generates dsRNAs during the virus life cycle. DNA 
viruses also make dsRNAs by transcription. In plants and 
invertebrates, the aim is viral mRNAs and genomic RNAs 
by RISC binding and their cleavage and degradation, thus 
blocking virus replication (Figure 7) (Bagasra, 2005).
Plant and Invertebrate Viruses Can Block 
Antiviral RNAi
The tomato bushy stunt virus p19 protein inhibits 
RNAi through direct binding of 21 bp dsRNAs with 2-nt 
39 overhangs, thus stopping the siRNAs (Akashi et al., 
2004). The cucumber mosaic cucumo virus 2b protein 
is able to inhibit RNAi by interfering with RISC, by 
inhibition of the RdRP-derived viral siRNAs and signaling 
(Matthew, 2004). Some insect viruses like the flock house 
virus (FHV) B2 protein, inhibits RNAi by direct binding 
of dsRNAs and also block viral siRNA by direct action 
with the viral RdRP in viral RNA synthesis (Dzianott et 
al., 2012).
Mammalian Cells Have an Antiviral RNAi 
Response
Cloned small RNAs from cell lines infected 
with a range of viruses including Kaposi’s sarcoma-
associated herpesvirus (KSHV), mouse g-herpesvirus 
68 (MHV68), human cytomegalovirus (hCMV), human 
immunodeficiency virus (HIV-1), YFV, and HCV. They 
show that HIV-1, YFV, and HCV produce neither viral 
miRNAs nor siRNAs in infected cells (Mueller et al., 
2010). Similar small RNA cloning, reported a similar 
absence of viral siRNAs in cells infected by HIV-1, human 
T-cell leukemia virus type I (HTLV-I), HCV, hCMV, 
murine cytomegalovirus (mCMV), EBV, and influenza 
virus (Bagasra, 2005).
RNAi Play a Role as an Innate Antiviral 
Immunity
Antiviral RNAi was first identified in Drosophila 
cell culture, where the beetle Nodamura virus FHV 
(flock house virus) acts as both an initiator and a target 
of the viRNA pathway. It was later mentioned, using 
the natural host–virus combination of O’nyong-nyong 
virus (alphavirus; Togaviridae) and Anopheles gambiae 
mosquitoes (Merkling et al., 2013). 
Viral Suppression and Evasion of the viRNA 
Pathway
The Hc-Pro protein of plant Poty viruses and the 2b 
protein of plant cucumo viruses were identified as VSRs 
(Mallory et al., 2001). The first VSR identified in an animal 
virus was the B2 protein of the beetle virus FHV, which 
was introduced to block RNAi in plants, before being 
studied to play the same role in insect (Pandya et al., 2013). 
Figure 7. Role of RNAi as an Antiviral (Haasnoot et 
al., 2007)
Table 2. Pre-miRNA Encoded by Viruses
Virus Family  Name Host No. of
    Subfamily/Genus   pre-miRNAs
Herpesvirus
 α/Simplexvirus HSV-1, HSV-2 Human 6,3
 α/Mardivirus MDV-1, MDV-2 Avian 14 ,17
 β/Cytomegalovirus hCMV, mCMV Human,Murine 11 ,18
 γ1/Lymphocryptovirus EBV Human 25
 γ2/Rhadinovirus rLCV, KSHV Simian,Human 16 ,12
Polyomavirus SV40,  Simian,
  BKV,  Human,
  JCV Human 1
Adenovirus hAV Human 1
*As each pre-miRNA may give rise to one or two mature miRNAs, this table 
enumerates the pre-miRNAs encoded by each virus. Only herpesviruses have 
so far been shown to encode more than one pre-miRNA. Several other viruses, 
including human papillomavirus,HCV, YFV, HIV-1, and HTLV-I, have been 
reported to lack miRNAs
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Viral mRNA Targets of Viral miRNAs
miRNAs have several usages, first of all they are target 
specific genes. Second, the evolution of a miRNA to a 
new target gene is more easily than the regulatory protein. 
Third, miRNAs are small for the tight space to viral 
genomes. Finally miRNAs are not antigenic (Umbach et 
al., 2009). All herpesviruses, human adenovirus, Heliothis 
virescens ascovirus (HvAc), and several members of the 
polyomavirus family encode miRNAs (Gorbatyuk et al., 
2010). Interestingly, most of the viral mRNA aiming viral 
miRNAs are targets of the host immune response and/
or viral regulatory proteins. For example, SV40 miR-S1 
shuts down production of the viral T antigen (TAg) as 
an early protein, which regulates viral transcription and 
DNA replication. During late viral replication, TAg can 
provoke a cytotoxic T-cell (CTL) response against SV40-
infected cells. The miR-S1 locating antisense to the TAg 
mRNA cleaves and degrades TAg mRNA (Cantalupo 
et al., 2005). The genomic location of SV40 miR-S1 
is conserved in other members of the polyomavirus 
family, such as human viruses JCV and BKV, mouse 
polyomavirus (mPy), and the primate SA12 and Merkel 
cell virus (MCV) and suppress TAg expression in their 
similar viruses (Broekema et al., 2013). 
In EBV the first target of viral miRNA is mRNA 
encoding the EBV DNA polymerase, BALF5, which 
is blocked by EBV miR-BART2. The miR-BART2 is 
antisense to BALF5, and thus acts as a siRNA cleaving 
the target transcript in the center of binding site (Malterer 
et al., 2011). In the insect virus HvAc produces a miRNA 
that shuts down the viral DNA polymerase. Unlike EBV 
miR-BART2, this HvAc miRNA is not antisense to the 
polymerase and binds the target (Mierlo et al., 2011). The 
miRNA for hCMV is miR-UL112-1 that can target the 
viral gene IE1 which is an immediate-early gene product 
requiring for activating transcription of hCMV early 
genes. When miRUL112- 1 expressed early in hCMV 
infection, a decrease in viral replication was observed 
(Weiwei et al., 2009).Herpes Simplex Virus Type 1 
(HSV-1) causes long term latent infections in neurons. 
HSV-1 express two miRNAs in latently infected neurons 
which caballing of ICP0 and ICP4 down-regulating, 
mmediate early proteins (Hill et al., , 2009). The miR-H2, 
is transcribed antisense to ICP0, while a second HSV-1 
miRNA, miR-H6, targets ICP4 mRNA. The miR-H3 and 
miR-H4, are both transcribed antisense to a viral mRNA 
encoding ICP34.5, which is a neurovirulence factor 
(Lukiw et al., 2010; Munson, 2012). HSV-2 miR-H3 
and miR-H4 are similar to HSV-1 miR-H3 and miR-H4i 
and inhibit ICP34.5 expression (Bagasra, 2005). HSV-1 
miR-H6, which is expressed during latency, suppress 
ICP4, a second immediate–early protein required for viral 
replication, suggests that these viral miRNAs are critical 
for HSV-1 and HSV-2 latency in vivo (Hong et al., 2006; 
Munson, 2012).
Cellular Targets of Viral miRNAs
It is possible for a single viral miRNA to block both 
viral and cellular mRNAs. For example hCMV miR-
UL112-1 suppresses both viral IE1 expression and cellular 
MICB expression. The region of miR-H2 in HSV is 
conserved and it is possible that this viral miRNA down-
regulate both viral ICP0 mRNA and a similar set of cellular 
transcripts (Leucci et al., 2010; Malterer et al., 2011). In 
apoptosis regulators include pro apoptotic factor (PUMA), 
which is a target of EBV miR-BART5 (Chatterjee et 
al., 2013). Suppression of PUMA by miR-BART5 may 
protect EBV infected cells from virus-induced apoptosis. 
BCLAF1, another apoptotic factor is a cellular target of 
the KSHV miRNAs miR-K5, miR-K9, and miR-K10 
which raises the levels of BCLAF1 and decreased virus 
production after induction of viral replication (Tian et al., 
2009; Weiwei et al., 2009). THBS1 is blocks by multiple 
KSHV miRNAs, including miR-K1, miRK3- 3p, miR-
K6-3p, and miR-K11 may help KSHV-infected cells in 
avoiding detection by the host immune system (Malterer 
et al., 2011; Wu et al., 2011). Another example of immune 
regulator is chemokine CXCL-11, which is a target of 
EBV miR-BHRF1-3 might allow infected cells to avoid 
T-cell detection and killing (Malterer et al., 2011). MICB 
is a stress-induced cell surface ligand, and the hCMV 
miRNA miR-UL112-1 was reported by Stern-Ginossar 
et.al to inhibit the expression of MICB by binding sites 
within the 39UTR of this mRNA. So, down-regulation 
of MICB by miR-UL112-1 may allow hCMV to escape 
NK cell immune surveillance (Malterer et al., 2011; Qiu 
et al., 2011; Weiwei et al., 2009). 
Antiviral Cellular miRNAs and Viral Tropism
Mammalian cells might inhibit virus infection by 
targeting viral transcripts with cellular miRNAs. This 
is very difficult for a cellular miRNA to stop a virus 
effectively, given that a single nucleotide mutation in the 
region of the viral mRNA target has the potential to block 
down regulation. For example some RNA viruses such as 
HIV-1 and HCV which are ‘pseudo species’’ (Zhou and 
Rossi, 2011). In mice was demonstrated a reduced level 
of Dicer activity become hyper susceptible to infection by 
vesicular stomatitis virus (VSV) due to reduced levels of 
cellular miR-24 and miR-93, which blocks VSV protein 
expression (Hosono et al., 2008).
Several cellular miRNAs, including miR-28, miR-
125b, miR-150, miR- 223, and miR-382, are able to inhibit 
HIV-1 replication by binding sites located within the viral 
genome (Vlachakis et al., 2013). Cellular miRNAs can 
affect viral tropism is provided by HCV which contains 
two adjacent binding sites for cellular miR-122 within 
its 59UTR. Unlike 39UTR miRNA-binding sites, which 
inhibit translation of target transcripts, binding of miR-
122 to the viral 59UTR helps HCV replication (Shwetha 
et al., 2013).Base on miR- 122 expressing in the liver the 
primary replication site of HCV, suggests that this cellular 
miRNA plays a main role in determining the tropism of 
HCV for this tissue (Shwetha et al., 2013).
KSHV encodes a viral miRNA, miR-K11 that not 
only has the same seed as miR-155, but also down-
regulation many cellular mRNAs. An accidental result 
of the virus-induced expression of miR-155 is that EBV-, 
KSHV-, or MDV-1-infected cells may cause oncogenic 
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transformation (Eichelser et al., 2013; Ferrajoli et al., 
2013).
RNAi Against Hepatitis B and Hepatitis Delta 
Viruses
Hepatitis B virus (HBV) is one of the major causes 
of liver disease worldwide, and chronic HBV infection 
can progress to cirrhosis and hepatocellular carcinoma 
.About 5% of the global population (350 million persons), 
are currently infected with HBV(Afshar and Mollaie, 
2012b). Chronic HBV can be treated with a nucleoside 
analogue, lamivudine, which in the short term can inhibit 
HBV replication by blocking the viral polymerase activity 
(Afshar and Mollaie, 2012a).
Transfection of siRNA against hepatitis B surface 
antigen (HBsAg) region into HepG2.2.15 cells reduces 
more than 80 per cent of HBsAg and HBeAg secretion 
in the culture medium and also in a mouse model, which 
produces HBV particles on injection with HBV plasmid, 
co-administration of the plasmid and siRNA blocked the 
virus specific transcripts, antigens and DNA in mouse 
liver and sera (Huang et al., 2005; Jiang et al., 2010). 
HBV viral replication inhibited by synthesized siRNA 
in a human epatoblastoma cell line, producing infectious 
HBV particles, The secretion of HBsAg into culture media 
measured and shows that target selection plays an main 
role in the success of RNAi process; but no systematic 
method is available yet to predict which targets would 
be more effective than the others (Konishi et al., 2003; 
2006). Four candidate shRNA plasmids significantly 
block HBV genotypes A, B, C, D and I in vitro and in 
vivo. A combination strategy of various siRNA in a single 
transcript done to improve efficacy and also delay the rise 
of viral escape mutants (He et al., 2006).
In a study used siRNA against the core region of HBV 
co-transfected with the full-length HBV DNA into Huh-7 
and HepG2 cells, demonstrated that HBeAg levels in the 
cell culture medium fell about 5-fold. Also, a Southern 
blot for the levels of replication elements showed a 
decrease when compared to control siRNAs against GFP 
(Konishi et al., 2003; Yang et al., 2010). RNAi sequences 
can be designed to get effective reduction in cell and 
animal models. Different constructs with the same RNAi 
sequences had different capacity in their activities in vitro 
and in vivo. Sequence, stability, ways of delivery is all 
important (Sun et al., 2010).
Plasmid-based RNAi expressed under the control of 
H1 RNA promoter from a plasmid against HBV Core and 
X genes. Using the core and X gene expression vectors 
along with the RNAi construct and a significant reduction 
in the levels of these proteins reported by Western blots 
(Shlomai et al., 2004; 2009). When HBV vector was co-
injected with siRNAs against either the core gene or the 
surface protein gene, the HBsAg levels or the HBeAg 
levels were reduced (Han et al., 2011). SiRNAs targeted 
the S gene of HBV are effective against HBV both in cell 
culture and in mouse models in vivo as evaluated by HBV 
antigen and DNA levels (He et al., 2010). Delta antigen 
mRNA can be aimed by siRNAs in cell culture. However, 
the genomic and anti-genomic RNAs are resistant to 
siRNA action (Tang et al., 2008). 
RNAi Against Hepatitis C Virus
HCV is divided into six major genotypes and more 
than 80 subtypes. 30-50% variation among genotypes 
and 15-30% among subtypes while 1-5% variation in 
nucleotide sequence from a single HCV infected patient. 
The hypervariable region is in E1 and E2 and the lowest 
variability is found in the 5’ untraslated region (UTR) 
containing RNA secondary structures which are required 
for replication and translation functions (Keyvani et al., 
2012). HCV RNA sub genomic replicon can be used 
that has a Neomycin resistance gene for selection and 
a luciferase gene for monitoring the levels of replicon 
expression. A fall (85-90%) in the levels of luciferase was 
detected if cells were transfected with siRNAs specific for 
either the 5’-UTR or the luciferase, whereas nonspecific 
control siRNAs or siRNAs with three nucleotide mismatch 
to the luciferase target failed to show any reduction. To 
verify that siRNAs do not cause cellular toxicity, they also 
studied cellular ATP levels and found them unchanged 
between transfected and mock-transfected cells (Seo et 
al., 2009). siRNAs can be used as a potent approach to 
decrease HCV replication in a sequence-specific manner. 
Six siRNAs targeting regions of HCV non-structural genes 
reported and examined their effect on viral replication 
(Jahan et al., 2011). HCV NS3si-229 and NS5Bsi-241 
showed greater than 50% inhibition in viral titer, while 
NS2si- 241 exhibited only 27% reduction in viral titer. 
Effect of siRNAs against HCV non- structural genes 
on HCV viral titer reduction is possibly because of the 
simultaneous degradation of HCV genomic RNA (Idrees 
et al., 2013). A sub genomic replicon system derived 
from HCV genotype 1b and siRNAs can be used against 
to NS3 and NS5B, showed 5.7- and 8.3-fold reduction, 
respectively, as reported by real-time PCR 2 days after 
transfection. The levels of NS3 and NS5B proteins were 
unchanged after 2 days by Western Blot analysis. They 
also compared the HCV RNA replication inhibition by 
RNAi and IFN treatment and found that siRNAs did 3-fold 
better than IFN and that the antiviral effect of siRNA is 
independent of IFN (Takigawa et al., 2004; Konishi et al., 
2006). Hepatitis C virus replicon system supports HCV 
replication but does not produce infectious virus in Huh-7 
hepatoma cells. siRNA transfection of these cells decrease 
the HCV specific RNA synthesis by 80-fold and cured >98 
per cent of cells (Trejo-Avila et al., 2007). A similar RNA 
replicon system, demonstrating 5-fold decrease in 12 h and 
an 80-fold decrease in 96 h in HCV RNA levels detected 
by real-time PCR when siRNAs against 5’-UTR were used 
(Wang et al., 2006). The siRNA against NS5B about 90% 
reduction in HCV RNA levels 72 h post-transfection using 
Northern blot analysis. Also the nonstructural proteins 
NS3 and NS5B were not in high levels as measured by 
immunoblotting (Wilson, 2006). 
In a study was choose five targets against 5’-UTR 
and showed siRNA-331 suppressing HCV replication by 
81% at a concentration of 2.5 nM and the suppression 
rate increased to 94% at 125 nM. The siRNA-expressing 
vectors suppressed HCV replication, but the stem-loop 
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type was more efficient than the tandem type (Yokota et 
al., 2007).
RNAi Against Hepatitis A Virus
Hepatitis A virus (HAV) is a major cause of acute liver 
difunction in children in the world. HAV RNA replication 
in HuhT7 cells was inhibited by siRNA. Combinations of 
siRNAs directed against two different genes were more 
useful and these treatments did not change expression 
of endogenous cellular genes. The viral infectivity shut 
downed after using a siRNA targeting hairpin structure. 
This siRNA is a therapeutic tool for severe courses of 
HAV infection. In addition, the results show new insight 
into the structural bases for sequence specific RNAi (Wu 
et al., 2004).
RNA Interference and Inhibition of Viruses
JC virus, a member of the genus polyomavius, causes 
progressive multifocal leukoencephalopathy.Human 
astrocyte cells transfected with siRNAs directed against 
T antigen or Agno protein coding mRNAs. Individually, 
siRNAs were partially effective but combined treatment 
of both siRNAs completely revoked JC virus capsid 
protein production. Similarly, siRNAs can cause inhibition 
of viral capsid protein VP1 and Agno protein by JC 
virus production in human glial cells (Cantalupo et al., 
2005). The effect of RNAi on JCV production based on 
hemagglutination activity of JCV-infected SVG-A cells 
36 h after siRNA transfection. The hemagglutination 
activities of cells transfected with Ag122, VP274, or both 
of these siRNAs were 6.7, 9.3, and 4.1%, respectively. 
Thus, siRNAs that target Agno protein or VP1 block 
JCV production in infected cells. The results may have 
important suggestion for the development of a new 
approach to the treatment of PML (Suzuki et al., 2010; 
Broekema et al., 2013).
Foot and mouth disease virus (FMDV) is an animal 
virus. Transfection of siRNA expressing plasmid showed 
80-90 per cent fall in expression of VP1 protein of FMDV 
in BHK-21 cells. Subcutaneous injection of this plasmid 
in suckling mice also protected the mice against lethal 
FMDV challenge (Ferrer et al., 2009).
Poliovirus Escapes from RNA Interference by a single 
substitution in viral RNA is enough to submit siRNAs 
ineffective within only a few replication cycles, even at 
highly conserved regions (Gitlin et al., 2005). SiRNA can 
stop gene expression to make a technology for antiviral 
gene therapy. There are RNAi against Coxsackievirus B3 
(CVB3) infection and evaluated the effects of RNAi on 
viral replication in HeLa cells and murine cardiomyocytes 
by using five CVB3-specific siRNAs targeting regions of 
the viral genome (Yuan et al., 2010). There is evidence that 
siRNA can knock-down human cytomegalovirus (HCMV) 
genes in various cell culture systems. This involved 
RNA transfection, even in growth-arrested primary 
human fibroblasts (Bagasra, 2005). In Herpes Simplex 
Virus Type 1 (HSV-1) siRNA can inhibit glycoprotein E 
expression and function during active infection in vitro 
and established RNAi as a genetic tool for the study of 
HSV and provided novel antiviral therapy (Prakash et al., 
2010). The inhibition of murine herpesvirus 68 replication 
by siRNAs against sequences encoding Rta, an immediate-
early protein, as a conserved viral protein. The results 
show that RNAi can block gamma herpesvirus replication 
(Kayhan et al., 2007). Specific siRNAs for influenza 
genomic regions were used in cell culture, eggs and in 
infant mice. Of the several siRNAs investigations, those 
specific for nucleoprotein (NP) and polymerase acidic 
(PA) genes of influenza virus could inhibit both, PR8 and 
WSN strains of influenza virus. The same siRNAs can 
stop influenza virus in embryonated eggs. The NP and PA 
siRNA treatment reduced virus titer in lung and saved the 
mice against lethal virus challenge (Barik, 2010). 
The NP- or PA-specific siRNA interfered with NP- or 
PA-specific mRNA, and NP- or PA-specific cRNA and 
vRNA. when siRNA give to mice either before or after 
virus infection, siRNA decrease influenza virus activity 
in the lungs (Truong et al., 2013). Sequence-specific M1 
siRNA could be used to inhibit viral protein synthesis 
and viral replication. It suggests that lentivirus vector 
expression of siRNA is useful for targeting the complex 
interaction of viral and cellular regulatory proteins (Hui 
et al., 2004). The silencing capacity of seven synthetic 
siRNAs against SARS-CoV leader, TRS, 3’-UTR and 
Spike coding sequence to prevent SARS-CoV infection, 
that siRNAs directed against Spike sequences and the 
3’-UTR can block the replication of SARS-CoV in 
Vero-E6 cells (Wu et al., 2005). In adeno virus siRNAs by 
improving suppressed adenovirus-mediated cytotoxicity 
against two late genes with the siRNA against the E1A 
early gene. The RNAi-based inhibition strategies can be 
used by co-silencing of early and late adenoviral genes, 
with down regulation of the E1A (Cruz et al., 2007).
Dengue virus replication and transmission was 
decreased by expressing RNAi in Aedes aegypti 
mosquitoes. Studies to develop transgenic mosquitoes that 
express dengue virus specific siRNA in targeted tissues 
are ongoing with final aim to reduce vector competence 
for dengue virus transmission (Idrees et al., 2013). In 
Measles Virus can be used siRNAs against N, P, and L, 
hemagglutinin (H) and fusion (F) mRNAs and reduced 
the cell-cell fusion. This siRNA-mediated knockdown 
of the matrix (M) protein not only enhanced cell-cell 
fusion but also increased the levels of both mRNAs and 
genomic RNA by a factor of 2 to 2.5 so that the genome-
to-mRNA ratio was constant. Studies indicate that M 
acts as a negative regulator of viral polymerase activity, 
affecting mRNA transcription and genome replication to 
the same extent (Otaki, 2007). It is also possible to target 
siRNAs to selectively reduce cellular mRNAs, proteins 
of which interact with viral proteins or in some ways are 
vital for virus replication (Bagasra, 2005). Cellular CCR5, 
a chemokine receptor, acts as a co-receptor for majority 
of primary HIV-1 isolates. Lentivirus vector was used for 
stable intracellular expression of siRNA against CCR5. 
These cells were survived. Some HIV-1 use CXCR4 
as co-receptor. Transfection of siRNA against CXCR4 
suppress CXCR4 expression on cell surface (Boutimah et 
al., 2013). The siRNA targeted against HIV tat protein, a 
trans activator, was tested to protect against HIV-1. It was 
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found that antiviral activity of short hairpin siRNA against 
tat was revoked subsequently because of quasispecies by 
point mutation in target sequences. This show that siRNA 
should be directed against multiple targets and against 
conserved sequences for inhibitory activity. This is true 
for mutating viruses like HIV that make escape mutants 
(Zhou, 2012; Vlachakis et al., 2013).
Conclusions 
The discovery of the miRNA and siRNA pathways 
has begun to change our knowledge of virus–host cell 
interactions. Although the role of miRNAs and siRNAs 
in virally infected cells is not complete, it is clear that 
both viruses and host cells using these systems play an 
important role in both host innate antiviral defense and 
virus replication. Future studies of these interactions 
in plants, invertebrates, and mammals will continue to 
increase our understanding of the viral interaction with 
the host antiviral innate immune response (Morris et al., 
2006; Jankovic et al., 2009). This review shows that RNAi 
can be used against different viruses. Both cell culture 
experiments and in vivo studies support this matter. While 
synthetic siRNAs have some effects, the plasmid-based 
siRNAs have been shown to induce stronger response.
According to studies, no IFN-related side effects have been 
reported in vivo in animal that got RNAi. Suitable levels of 
interferon system activation in a therapeutic setting should 
be decided and the lowest effective dose of siRNA should 
be used because nonspecific induction of IFN by RNAi 
depends on the quantity of siRNA (Ma et al., 2005; Wang 
et al., 2013). Like other therapeutic strategy, effective 
delivery presents a major impediment before RNAi can 
be adapted to clinical trials. Chemical components of 
siRNAs may need to increase their half-life. Another aim 
would be to mix the siRNAs with liposomes along with a 
small peptide that can bind to a specific receptor.RNAi is 
sensitive to mismatches in the target regions. As low as 
a single-base mismatch can abolish RNAi activity. It is 
an issue when RNAi is used as a therapy because viruses 
may become resistant by altering their nucleotides in 
the target region. This is especially true in some viruses 
where the RNA-dependent RNA polymerase (RdRP) lacks 
proofreading activity and it causes large number of errors 
during viral replication. This problem of escape viruses has 
been observed in the case of poliovirus and more recently 
in the case of HIV (Gitlin et al., 2005).
The theory is raised that mutations happen for escaping 
viruses when the suppression against viral levels is not 
complete. For example, in the case of chronic hepatitis C 
where the viral levels are between 105 and 107 genome 
copies/ml of blood becoming resistant to therapy by 
acquiring mutations in the target region. Thus, it is 
necessary to target more than one region by using a mixture 
of different siRNAs or combine different techniques such 
as ribozymes and antisense oligonucleotides along with 
RNAi as a combined therapeutic approach to fight the 
virus (Konishi et al., 2006; Jahan et al., 2011). RNA 
interference is an extremely potent and skilled tool to 
reduce expression of targeted genes. Using this technology 
has moved from in vitro cell culture studies to in vivo 
administration in mammals. It is becoming clear that 
especial controls should be performed when using siRNAs 
in vivo to prevent the risk of misinterpreting results due 
to unplanned stimulation of the innate immune system or 
wrong target effects. Measurement of serum IFN-a, TNF-a, 
and possibly IL-12 levels should be thought, especially 
when systemic administration methods are used. Some 
researchers have reported success administration of naked 
siRNAs, a greater number of studies reported that using 
some kind of delivery system improved results. Different 
ways of administration and their selection of best delivery 
tool will be important to success.
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